Anne Doherty1, Jose C A Carvalho2, Sascha Drewlo3, Afif El-Khuffash4, Kristi Downey1, Madelaine Dodds5, John Kingdom3. 1. Department of Anesthesia, Mount Sinai Hospital, University of Toronto, Toronto ON. 2. Department of Anesthesia, Mount Sinai Hospital, University of Toronto, Toronto ON; Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto ON. 3. Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto ON; The Lunenfeld-Tannenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto ON. 4. Department of Neonatology, Mount Sinai Hospital, University of Toronto ON. 5. Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto ON.
Abstract
OBJECTIVE: Early identification of women at risk of developing early-onset severe preeclampsia (sPE) is a key objective in obstetrics. An elevated ratio of serum soluble fms-like tyrosine kinase (sFlt-1) to placenta-like growth factor (PlGF) (sFlt-1/PlGF ratio) precedes overt hypertension. The longitudinal relationship between this biomarker, maternal hemodynamics, and maternal serum uric acid during the pre-clinical phase is unknown. STUDY DESIGN: We followed 20 normotensive women at high risk of developing sPE from 20 weeks until delivery or 34 weeks' gestation. Non-invasive hemodynamic monitoring using bioreactance technology was performed at 20 to 22, 24 to 26, 28 to 30, and 32 to 34 weeks' gestation. Serum uric acid, sFlt-1, and PlGF were measured simultaneously. RESULTS: Six of 20 women (30%) delivered before 33 weeks with sPE and had significantly higher mean total peripheral resistance (TPR), higher serum uric acid, and higher sFlt-1/PlGF ratios at 24 weeks' gestation than unaffected individuals. The area under the curve, cut-off values, and sensitivity and specificity to predict sPE at 24 weeks were as follows: TPR 0.84, 1250 dyne.s.cm-5, 80%, 93%; sFlt-1/PlGF ratio 0.94, 55, 100%, 93%; and serum uric acid 0.99, 255 μmol/L, 100%, 93%. TPR and sFlt-1 were positively correlated in the sPE group before antihypertensive treatment (r = 0.65, P = 0.01). Serum uric acid correlated with both sFlt-1 (r = 0.65, P = 0.003) and sFlt-1/PlGF ratio (r = 0.54, P = 0.02). CONCLUSION: A combination of non-invasive determination of TPR together with measurement of serum uric acid may identify a subset of clinically high-risk women with evolving sPE, independent of the determination of the sFlt-1/PlGF ratio. The predictive ability of this integrated approach needs to be assessed in a larger cohort of women to further confirm its utility.
OBJECTIVE: Early identification of women at risk of developing early-onset severe preeclampsia (sPE) is a key objective in obstetrics. An elevated ratio of serum soluble fms-like tyrosine kinase (sFlt-1) to placenta-like growth factor (PlGF) (sFlt-1/PlGF ratio) precedes overt hypertension. The longitudinal relationship between this biomarker, maternal hemodynamics, and maternal serum uric acid during the pre-clinical phase is unknown. STUDY DESIGN: We followed 20 normotensive women at high risk of developing sPE from 20 weeks until delivery or 34 weeks' gestation. Non-invasive hemodynamic monitoring using bioreactance technology was performed at 20 to 22, 24 to 26, 28 to 30, and 32 to 34 weeks' gestation. Serum uric acid, sFlt-1, and PlGF were measured simultaneously. RESULTS: Six of 20 women (30%) delivered before 33 weeks with sPE and had significantly higher mean total peripheral resistance (TPR), higher serum uric acid, and higher sFlt-1/PlGF ratios at 24 weeks' gestation than unaffected individuals. The area under the curve, cut-off values, and sensitivity and specificity to predict sPE at 24 weeks were as follows: TPR 0.84, 1250 dyne.s.cm-5, 80%, 93%; sFlt-1/PlGF ratio 0.94, 55, 100%, 93%; and serum uric acid 0.99, 255 μmol/L, 100%, 93%. TPR and sFlt-1 were positively correlated in the sPE group before antihypertensive treatment (r = 0.65, P = 0.01). Serum uric acid correlated with both sFlt-1 (r = 0.65, P = 0.003) and sFlt-1/PlGF ratio (r = 0.54, P = 0.02). CONCLUSION: A combination of non-invasive determination of TPR together with measurement of serum uric acid may identify a subset of clinically high-risk women with evolving sPE, independent of the determination of the sFlt-1/PlGF ratio. The predictive ability of this integrated approach needs to be assessed in a larger cohort of women to further confirm its utility.
Entities:
Keywords:
NICOM; PlGF; bioreactance; early severe preeclampsia; sflt -1; uric acid; vascular resistance
Authors: Ayub Akbari; Michelle Hladunewich; Kevin Burns; Felipe Moretti; Rima Abou Arkoub; Pierre Brown; Swapnil Hiremath Journal: Can J Kidney Health Dis Date: 2016-02-23
Authors: Kelsey McLaughlin; John W Snelgrove; Laura E Sienas; Thomas R Easterling; John C Kingdom; Catherine M Albright Journal: J Am Heart Assoc Date: 2022-03-14 Impact factor: 6.106
Authors: Rachel M Wald; Candice K Silversides; John Kingdom; Ants Toi; Cathy S Lau; Jennifer Mason; Jack M Colman; Mathew Sermer; Samuel C Siu Journal: J Am Heart Assoc Date: 2015-11-23 Impact factor: 5.501